Skip to search formSkip to main contentSkip to account menu

ONO-4059

Known as: BTK Inhibitor ONO-4059, Bruton's Tyrosine Kinase Inhibitor ONO-4059 
An orally available formulation containing an inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

GS-4059
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)
Recent therapeutic advances for mantle cell lymphoma (MCL) include inhibitors of Bruton’s tyrosine kinase (BTK), a critical… 
2019
2019
Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction.
Review
2017
Review
2017
Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia
ABSTRACT Introduction: Over the last few years, several new synthetic drugs, particularly Bruton’s tyrosine kinase (BTK… 
Review
2014
Review
2014
Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials
BTK is a cytoplasmic, non-receptor tyrosine kinase that transmits signals from a variety of cell-surface molecules, including the… 
2014
2014
The Bruton’s Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL)
Introduction Bruton’s tyrosine kinase (BTK) is a critical kinase involved in B-cell receptor signal transduction. ONO-4059, a… 
Review
2013
Review
2013
Ibrutinib and novel BTK inhibitors in clinical development
Small molecule inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved… 
2013
2013
A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory and High Risk Chronic Lymphocytic Leukaemia (CLL)
Introduction The B-cell receptor (BCR) pathway plays a central role in signal transduction pathways that regulate survival… 
2013
2013
ONO-4059, A Novel Bruton’s Tyrosine Kinase (Btk) Inhibitor: Synergistic Activity In Combination With Chemotherapy In a ABC-DLBCL Cell Line
Purpose Bruton’s tyrosine kinase (Btk) is a key regulator of the B-cell receptor (BCR) signaling pathway and abberant BCR… 
2013
2013
A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma
Introduction The B-cell receptor (BCR) pathway plays a central role in signal transduction pathways that regulate survival… 
2013
2013
Abstract 2452: ONO-4059, a novel oral Bruton's tyrosine kinase (Btk) inhibitor that demonstrates potent pharmacodynamic activity through Phosphorylated Btk (P-Btk) inhibition, in addition to…
Purpose: The B-cell receptor (BCR) pathway plays a central role in signal transduction pathways that regulate survival… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)